Introduction {#sec1-0300060520904863}
============

Breast cancer is regarded as the most common cancer among women, and about 6.6% of cases are diagnosed among women 40 years old or younger.^[@bibr1-0300060520904863]^ Breast cancer accounts for 40% of all types of cancers diagnosed in women and is the third-leading cause among all cancer deaths in Western countries,^[@bibr2-0300060520904863]^ although the death rate has decreased in most developed countries with the help of improved treatments and earlier diagnosis.

Over the last few years, several mechanisms have been postulated regarding the etiology and progression of breast cancer.^[@bibr3-0300060520904863]^ It has been shown that chronic inflammatory responses play essential roles in development of all kinds of cancers. Inflammatory cells can regulate the tumor microenvironment and are clearly implicated in tumor development by facilitating proliferation, migration, and survival.^[@bibr4-0300060520904863],[@bibr5-0300060520904863]^ Several cytokines, including interferon-α, interleukin (IL)-2, IL-6, IL-8, IL-10, and tumor necrosis factor-α, have essential and coordinated functions in breast carcinogenesis.^[@bibr6-0300060520904863],[@bibr7-0300060520904863]^ As a multifunctional anti-inflammatory cytokine, IL-10 represses the inflammatory response to tumor microenvironments. It is usually secreted by immune cells, such as monocytes, T cells, macrophages (if stimulated appropriately), certain subsets of dendritic cells, and B cells.^[@bibr8-0300060520904863],[@bibr9-0300060520904863]^

The human *IL10* gene, containing five exons, is located on chromosome 1q32.1. The promoter region contains at least 40 polymorphic sites, and these sites may affect gene transcription.^[@bibr10-0300060520904863][@bibr11-0300060520904863]--[@bibr12-0300060520904863]^ An A-to-G single base pair substitution designated rs1800896 (−1082A/G) has been found in the *IL10* gene promoter region, located −1082 bp (upstream) of the transcriptional start site. The *IL10* −1082A/G polymorphism is closely connected to IL-10 expression.^[@bibr13-0300060520904863][@bibr14-0300060520904863]--[@bibr15-0300060520904863]^ However, there is currently no agreement on whether an association exists between breast cancer and the −1082A/G polymorphism. This meta-analysis was designed to clarify whether rs1800896 (−1082A/G) is associated with breast cancer risk through an investigative analysis of the published literature.

Methods {#sec2-0300060520904863}
=======

Identification and selection of studies {#sec3-0300060520904863}
---------------------------------------

Relevant studies from Medline (since 1 January 1966) and Embase (since 1 January 1974) through 1 September 2018 were systematically searched (by Z. Zhu and J.-B. Liu). Eligible studies were identified using the keywords "IL-10", "Interleukin-10", "-1082 A/G", "rs1800896", "polymorphism", "genotype", "mutation" "variant", and "breast cancer". Then, all references of retrieved studies, clinical trials, review articles, and previous meta-analyses were examined to identify relevant studies that may have been missed in the electronic database searches. The complete search strategy is shown in the supplementary data (Supplemental Document 1).

Eligibility criteria {#sec4-0300060520904863}
--------------------

Eligible studies had to meet the following criteria: (1) evaluated the connection between *IL10* −1082A/G polymorphism and breast cancer risk; (2) characterized by a case-control or cohort design; (3) provided enough data for calculation of odds ratios (ORs) and their 95% confidence intervals (95% CIs). If multiple studies presented the same data, only the study with the latest data, the largest sample size, or the completed study was included. The exclusion criteria were (1) review article, case report, or an abstract only; (2) studies without a case-control population or not a cohort design; (3) lack of essential data; (4) studies without a control group of healthy individuals; and (5) duplicates of previous prior articles.

Data collection and quality evaluation {#sec5-0300060520904863}
--------------------------------------

From the eligible studies, two authors (Z. Zhu and J.-B. Liu) independently collected relevant data, if available: first author, publication year, country of origin, ethnicity of patients, total numbers of cases and controls, genotype frequencies, genotyping technique, minor allele frequency, and *P*-value for Hardy--Weinberg equilibrium (HWE). For any disagreements between the two data sets, consensus was reached through discussion or following assessment by a third author. In control groups, confirmation of HWE was applied to assess the quality of study: high-quality studies have HWE confirmation in controls whereas low-quality ones do not.

Quality assessment of included studies {#sec6-0300060520904863}
--------------------------------------

The Newcastle--Ottawa Scale (NOS) of case-control studies was used to determine the methodological quality for each included study. The NOS contains eight elements, as shown in Supplemental Table 1.

Statistics {#sec7-0300060520904863}
----------

The correlation between the *IL10* −1082A/G polymorphism (rs1800896) and breast cancer risk was assessed by crude ORs with 95% CIs. A summary estimate of the OR was obtained by calculating the weighted average of the ORs for each study. The Z-test was carried out to assess whether the pooled OR was statistically significant. This meta-analysis was based on the allele model (A vs. G), the dominant model (AA vs. AG + GG), recessive model (AA + AG vs. GG), co-dominant heterozygote model (AA vs. AG), co-dominant homozygote model (AA vs. GG), and the over-dominant model (AA + GG vs. AG). In the meta-analysis, heterogeneity between studies was assessed using the *I*^2^ value and the Q-statistic. The *I*^2^ value describes the degree of heterogeneity between studies. A value of 0 to 25% indicates no detected heterogeneity, 25% to 50% indicates lowly increased heterogeneity, 50% to 75% moderately increased heterogeneity, and 75% to 100% highly increased heterogeneity.^[@bibr16-0300060520904863],[@bibr17-0300060520904863]^ For the Q-statistic, a *P*-value \>0.10 indicates a lack of heterogeneity between studies. An estimate of pooled OR was determined by the fixed-effects model (Mantel--Haenszel method).^[@bibr18-0300060520904863]^ In addition, the random-effects model (DerSimonian and Laird method) was used.^[@bibr19-0300060520904863]^ Subgroup analyses, HWE status, and meta-regression were performed to adjust the heterogeneity between studies. In controls, a departure from HWE was evaluated using the χ^2^ test. A *P*-value \<0.05 represents statistical significance. Analyses of one-way sensitivity were made to evaluate the stability of results. That is, with each calculation, one study was removed from the meta-analysis so that the effect of an individual dataset on the pooled OR could be determined. Any potential publication bias was identified by using funnel plots and Egger's linear regression test.^[@bibr20-0300060520904863],[@bibr21-0300060520904863]^ To guarantee the accuracy and reliability of the results, data were entered independently by two researchers and consensus was reached. Comprehensive Meta-Analysis software version 2.20 (Stata Corp., College Station, TX, USA) was applied to perform all data analyses. All *P*-values were two-sided and considered significant if *P* \< 0.05.

Patient and public involvement {#sec8-0300060520904863}
------------------------------

There was no direct patient or public involvement in current study and therefore ethical approval and patient consent were not required.

Results {#sec9-0300060520904863}
=======

Study characteristics {#sec10-0300060520904863}
---------------------

As shown in [Figure 1](#fig1-0300060520904863){ref-type="fig"}, our search criteria returned 253 published articles. Fourteen studies,^[@bibr22-0300060520904863][@bibr23-0300060520904863][@bibr24-0300060520904863][@bibr25-0300060520904863][@bibr26-0300060520904863][@bibr27-0300060520904863][@bibr28-0300060520904863][@bibr29-0300060520904863][@bibr30-0300060520904863][@bibr31-0300060520904863][@bibr32-0300060520904863][@bibr33-0300060520904863][@bibr34-0300060520904863]--[@bibr35-0300060520904863]^ containing 5320 breast cancer-related cases and 5727 control cases, were identified. A meta-analysis database was established based on the information extracted from the 14 selected studies: 8 (57%) focused on Caucasian populations, 4 (29%) on Asian populations, 1 (7%) on African populations, and 1 (7%) had a mixed population.

![PRISMA flow chart depicting the procedure for the identification of studies.](10.1177_0300060520904863-fig1){#fig1-0300060520904863}

All 14 studies included cases and controls. Nine (64%) studies were population-based and 5 (36%) were hospital-based. They used a range of gene detection methods: PCR, restriction fragment length polymorphism (RFLP)-PCR, amplification-refractory mutation system (ARMS)-PCR, allele-specific (AS)-PCR), and sequence-specific amplification (SSP)-PCR. Sample size varied greatly across studies, from a minimum of 62 to a maximum of 4483. For controls, all genotype distributions were consistent with HWE for the *IL10* −1082 A/G polymorphism. Details are shown in [Table 1](#table1-0300060520904863){ref-type="table"}.

###### 

Characteristics of studies (listed by first author and year) included in the meta-analysis.

![](10.1177_0300060520904863-table1)

  Study                    Country      Ethnicity                   Control source                 Genotyping method        No. of cases                 No. of controls   HWE                                
  ------------------------ ------------ --------------------------- ------------------------------ ------------------------ ---------------------------- ----------------- ------ ------ ------ ------ ------ ---
  Giordani (2003)          Italy        Caucasian                   HB                             ARMS-PCR                 125                          100               0.61                               
  Smith (2004)             UK           Caucasian                   PB                             ARMS-PCR                 144                          263               0.24                               
  Guzowski (2005)          USA          Mixed                       HB                             PCR                      50                           25                1                                  
  Balasubramanian (2006)   UK           Caucasian                   PB                             PCR                      497                          498               0.32                               
  Scola (2006)             Italy        Caucasian                   HB                             SSP-PCR                  84                           110               0.21                               
  Onay (2006)              Canada       Caucasian                   PB                             PCR                      398                          372               0.31                               
  Pharoah (2007)           UK           Caucasian                   PB                             PCR                      2203                         2280              0.08                               
  Gonullu (2007)           Turkey       Caucasian                   HB                             PCR                      38                           24                0.83                               
  Kong (2010)              China        Asian                       HB                             RELP-PCR                 315                          322               0.42                               
  Schonfeld (2010)         USA          Caucasian                   PB                             PCR                      859                          1083              0.66                               
  Pooja (2012)             India        Asian                       PB                             RELP-PCR                 200                          200               NA                                 
  Vinod (2015)             India        Asian                       PB                             AS-PCR                   125                          160               0.25                               
  AlSuhaibani (2015)       Egypt        African                     PB                             PCR                      80                           80                NA                                 
  Atoum (2016)             Jordan       Asian                       PB                             PCR                      202                          210               NA                                 
                           Sampletype   Genotype frequency (case)   Genotype frequency (control)   Allelefrequency (case)   Allele frequency (control)   Quality score                                        
  Study                    GG           AG                          AA                             GG                       AG                           AA                A      G      A      G             
  Giordani (2003)          Blood        11                          54                             60                       16                           51                33     174    82     117    83     5
  Smith (2004)             Blood        39                          58                             32                       57                           120               46     122    136    212    234    4
  Guzowski (2005)          Blood        12                          28                             10                       4                            12                9      48     52     30     20     6
  Balasubramanian (2006)   Blood        121                         253                            123                      117                          260               121    499    497    502    494    3
  Scola (2006)             Blood        16                          40                             28                       21                           45                40     96     72     125    87     5
  Onay (2006)              Blood        103                         205                            90                       71                           194               107    385    411    408    336    4
  Pharoah (2007)           Blood        344                         1003                           695                      346                          1096              743    2393   1691   2582   2480   4
  Gonullu (2007)           Blood        3                           22                             13                       1                            7                 16     48     28     39     9      5
  Kong (2010)              Blood        1                           29                             285                      2                            35                285    599    31     605    39     6
  Schonfeld (2010)         Blood        200                         417                            219                      230                          530               322    834    817    1176   990    3
  Pooja (2012)             Blood        68                          0                              132                      55                           0                 145    264    136    290    110    4
  Vinod (2015)             Blood        18                          31                             76                       15                           78                67     183    67     212    108    3
  AlSuhaibani (2015)       Blood        17                          47                             16                       16                           50                14     81     79     82     78     4
  Atoum (2016)             Blood        16                          29                             157                      17                           42                151    343    61     344    76     3

HB, hospital-based; PB, population-based; RELP-PCR, restriction fragment length polymorphism-PCR; ARMS, amplification-refractory mutation system-PCR; AS-PCR, allele-specific-PCR; SSP-PCR, sequence-specific amplification-PCR; HWE, Hardy--Weinberg equilibrium.

Overall data {#sec11-0300060520904863}
------------

Fourteen separate studies, including 5320 breast cancer cases and 5727 control cases, were identified to explore associations. The key findings are demonstrated in [Table 2](#table2-0300060520904863){ref-type="table"}. There was an overall significant association as determined by both the recessive model (AA + AG vs. GG: OR = 0.88, 95% CI = 0.80--0.97; *P* = 0.01; [Figure 2a](#fig2-0300060520904863){ref-type="fig"}) and the co-dominant homozygotes model (AA vs. GG: OR = 0.88, 95% CI = 0.78--0.98; *P* = 0.03; [Figure 2b](#fig2-0300060520904863){ref-type="fig"}). The results showed an association of *IL10* −1082 G/G genotype with increased breast cancer risk. However, no obvious association was found between the frequency of the *IL10* −1082 A/G polymorphism and breast cancer as determined by the allele model (A vs. G: OR = 0.97, 95% CI = 0.87--1.08), the dominant model (AA vs. AG + GG: OR = 1.02, 95% CI = 0.85--1.21), the co-dominant heterozygotes model (AA vs. GA: OR = 1.09, 95% CI = 0.9--1.33), or the over-dominant model (AA + GG vs. AG: OR = 1.13, 95% CI = 0.97--1.32).

###### 

The meta-analysis of *IL10* −1082A/G polymorphism and breast cancer risk.

![](10.1177_0300060520904863-table2)

  Group            A vs. G             AA vs. AG + GG(dominant model)   AA + AG vs. GG\*(recessive model)   AA vs. AG (co-dominant heterozygotes model)   AA vs. GG\* (co-dominant homozygotes model)   AA + GG vs. AG(over-dominant model)                                                                             
  ---------------- ------------------- -------------------------------- ----------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------- ------------------- ------ ------------------- ------ ------------------- ------
  Overall          0.97 (0.87, 1.08)   0.55                             1.02 (0.85, 1.21)                   0.85                                          0.88 (0.80, 0.97)                             0.01                                  1.09 (0.90, 1.33)   0.38   0.88 (0.78, 0.98)   0.03   1.13 (0.97, 1.32)   0.12
  Ethnicity                                                                                                                                                                                                                                                                                                             
   Caucasian       0.94 (0.84, 1.06)   0.33                             0.95 (0.78, 1.14)                   0.56                                          0.89 (0.80, 0.99)                             0.04                                  0.97 (0.81, 1.16)   0.76   0.88 (0.78, 1.00)   0.05   1.03 (0.92, 1.16)   0.59
   Asian           1.10 (0.80, 1.52)   0.55                             1.27 (0.81, 1.98)                   0.3                                           0.78 (0.56, 1.07)                             0.12                                  1.73 (1.04, 2.86)   0.03   0.86 (0.62, 1.19)   0.35   1.73 (1.03, 2.91)   0.04
  Control source                                                                                                                                                                                                                                                                                                        
   HCC             0.94 (0.62, 1.44)   0.79                             0.85 (0.47, 1.53)                   0.58                                          1.18 (0.74, 1.88)                             0.48                                  0.84 (0.48, 1.48)   0.55   1.14 (0.69, 1.89)   0.61   0.91 (0.60, 1.38)   0.66
   PCC             0.95 (0.86, 1.04)   0.27                             1.02 (0.86, 1.22)                   0.81                                          0.87 (0.78, 0.96)                             0.01                                  1.14 (0.92, 1.42)   0.23   0.87 (0.77, 0.97)   0.02   1.18 (1.00, 1.40)   0.06
  Sample size                                                                                                                                                                                                                                                                                                           
   \<500           1.00 (0.80, 1.25)   0.99                             1.06 (0.74, 1.51)                   0.76                                          0.86 (0.69, 1.07)                             0.18                                  1.18 (0.76, 1.81)   0.46   0.94 (0.73, 1.20)   0.6    1.21 (0.83, 1.74)   0.32
   ≥500            0.93 (0.84, 1.02)   0.13                             0.93 (0.81, 1.07)                   0.3                                           0.88 (0.79, 0.99)                             0.03                                  0.97 (0.88, 1.08)   0.59   0.86 (0.76, 0.98)   0.03   1.03 (0.94, 1.12)   0.54

HCC, hospital-based case-control study; PCC, population-based case-control study.

\*AA + AG vs. GG and AA vs. GG, the fixed effect model due to the heterogeneity; otherwise, the random effect model.

![Forest plot of breast cancer risk in all studies (overall) associated with the *IL10* −1082A/G (rs1800896) polymorphism under (a) the recessive model (AA + AG vs. GG), and (b) the co-dominant homozygotes model (AA vs. GG). *IL10*, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.](10.1177_0300060520904863-fig2){#fig2-0300060520904863}

Subgroup analysis by ethnicity {#sec12-0300060520904863}
------------------------------

After stratifying the data for ethnicity, we observed that in Caucasian populations, based on eight studies (4348 patients and 4730 control cases), an obvious association was found between *IL10* −1082 G/G genotype and increased risk of breast cancer in the recessive model (AA + AG vs. GG: OR = 0.89, 95% CI = 0.80--0.99; *P* = 0.04; [Table 2](#table2-0300060520904863){ref-type="table"} and [Figure 3a](#fig3-0300060520904863){ref-type="fig"}) and the co-dominant homozygotes model (AA vs. GG: OR = 0.88, 95% CI = 0.78--1.00; *P* = 0.05; [Table 2](#table2-0300060520904863){ref-type="table"} and [Figure 3b](#fig3-0300060520904863){ref-type="fig"}). However, in Asian groups, there was no association between *IL10* −1082 G/G polymorphism and increased breast cancer risk in any model ([Table 2](#table2-0300060520904863){ref-type="table"}, [Figure 3a and 3b](#fig3-0300060520904863){ref-type="fig"}).

![Forest plot of breast cancer risk in ethnicity subgroups (Caucasian vs. Asian) associated with the *IL10* −1082A/G (rs1800896) polymorphism under (a) the recessive model (AA + AG vs. GG), and (b) the co-dominant homozygotes model (AA vs. GG). *IL10*, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.](10.1177_0300060520904863-fig3){#fig3-0300060520904863}

Subgroup analysis by study design {#sec13-0300060520904863}
---------------------------------

In the study design subgroups, pooled analyses of population-based case-control studies showed a close association of *IL10* −1082 G/G genotype with an increase in breast cancer risk based on the recessive model (AA + AG vs. GG: OR = 0.87, 95% CI = 0.78--0.96; *P* = 0.01; [Table 2](#table2-0300060520904863){ref-type="table"} and [Figure 4a](#fig4-0300060520904863){ref-type="fig"}) and the co-dominant homozygotes model (AA vs. GG: OR = 0.87, 95% CI = 0.77--0.97; *P* = 0.02; [Table 2](#table2-0300060520904863){ref-type="table"} and [Figure 4b](#fig4-0300060520904863){ref-type="fig"}). None of the ORs in hospital-based case-control studies were statistically significant ([Table 2](#table2-0300060520904863){ref-type="table"} and [Figure 4a and 4b](#fig4-0300060520904863){ref-type="fig"}).

![Forest plot of breast cancer risk in control source subgroups (hospital-based controls vs. population-based controls) associated with the *IL10* −1082A/G (rs1800896) polymorphism under (a) the recessive model (AA + AG vs. GG), and (b) the co-dominant homozygotes model (AA vs. GG). *IL10*, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.](10.1177_0300060520904863-fig4){#fig4-0300060520904863}

Subgroup analysis by sample size {#sec14-0300060520904863}
--------------------------------

We then stratified analyses by sample size, with a cutoff of 500 subjects (i.e., sample size \<500 vs. ≥500).^[@bibr36-0300060520904863]^ A higher risk of breast cancer was observed in studies with ≥500 subjects under the recessive model (AA + AG vs. GG: OR = 0.88, 95% CI = 0.79--0.99; *P* = 0.03; [Table 2](#table2-0300060520904863){ref-type="table"} and [Figure 5a](#fig5-0300060520904863){ref-type="fig"}) and the co-dominant homozygotes model (AA vs. GG: OR = 0.86, 95% CI = 0.76--0.98; *P* = 0.03; [Table 2](#table2-0300060520904863){ref-type="table"} and [Figure 5b](#fig5-0300060520904863){ref-type="fig"}). In the subgroup with sample size \<500, there were no significant changes in ORs in any of the genetic models.

![Forest plot of breast cancer risk in sample size subgroups (\<500 vs. ≥500 samples) associated with the *IL10* −1082A/G (rs1800896) polymorphism under (a) the recessive model (AA + AG vs. GG), and (b) the co-dominant homozygotes model (AA vs. GG).\
*IL10*, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.](10.1177_0300060520904863-fig5){#fig5-0300060520904863}

Publication bias {#sec15-0300060520904863}
----------------

To evaluate the potential publication bias of these studies, Egger's test and Begg's funnel plots were used. For the recessive (AA + AG vs. GG) and co-dominant homozygote (AA vs. GG) models, the findings from Begg's funnel plots showed no obvious asymmetry ([Figure 6a and 6b](#fig6-0300060520904863){ref-type="fig"}). The results of Egger's tests suggested no evidence of publication bias for the recessive (AA + AG vs. GG) and co-dominant homozygote (AA vs. GG) models (*t* = 0.50, *P* = 0.627; *t* = 0.85, *P* = 0.411, respectively).

![Begg's funnel plot of the publication bias test under (a) the recessive model (AA  +  AG vs. GG), and (b) the co-dominant homozygotes model (AA vs. GG). Each point represents a separate study for the indicated association.\
OR, odds ratio.](10.1177_0300060520904863-fig6){#fig6-0300060520904863}

Discussion {#sec16-0300060520904863}
==========

Main findings {#sec17-0300060520904863}
-------------

The findings from our meta-analysis of 14 studies, which involved 5320 cases and 5727 controls, indicated a significant correlation between the *IL10* −1082 G/G genotype and an increase in breast cancer risk. The significant association was confirmed in further analyses among the Caucasian subgroup, the population-based case-control subgroup, and the subgroup of sample size ≥500.

Tumors are closely associated with chronic inflammation.^[@bibr37-0300060520904863]^ The multifunctional cytokine IL-10 is secreted by T helper (Th)2 cells and has both immunosuppressive and anti-angiogenic functions, suggesting that IL-10 is involved in tumor development and progression. Some *in vitro* studies have shown that IL-10 promotes the proliferation and migration of MCF-7 breast cancer cells.^[@bibr38-0300060520904863]^ Low expression of *IL10* in tumor cells increases the risk of poor prognosis in breast cancer.^[@bibr39-0300060520904863]^ Studies have also shown that *IL10* −1082A/G polymorphisms (in the promotor region of *IL10*) affect IL-10 expression,^[@bibr40-0300060520904863]^ and that the −1082 G allele is associated with poorly differentiated adenocarcinoma of breast cancer.^[@bibr41-0300060520904863]^

Prior studies have explored the relationship between the *IL10* −1082A/G polymorphism and breast cancer risk but most failed to find a correlation. Some studies report that the AA genotype of the polymorphism is correlated with an increase in breast cancer risk,^[@bibr22-0300060520904863],[@bibr33-0300060520904863]^ which is inconsistent with the present study's findings. However, the limitations of those studies should be mentioned. Both included small sample sizes and only reported GG, GA, and AA instead of combined genotypes GG + GA and GA + AA. Our paper represents the most comprehensive meta-analysis on this issue, and it expands on prior meta-analyses by including a larger sample size as well as subgroup analyses. In particular, we believe that the present research is the most accurate meta-analysis to date because of the inclusion of a subgroup for study quality as determined by HWE status.

The incidence of gene polymorphisms can vary substantially across racial or ethnic populations with different genetic backgrounds, which influences measures of association between polymorphisms and cancer susceptibility. Subgroup analyses by ethnicity showed an obvious association between GG genotypes and an increased risk of breast cancer in Caucasian but not Asian populations. These finding suggests that genetic diversity or natural selection is occurring at different rates in different ethnicities. The sample size of the African population was too small to draw conclusions on associations.

Subgroup analyses indicate that differences in either study design or the number of subjects affect the calculated risk associations. Significant associations between GG genotypes and an increased risk of breast cancer were identified in the population-based case-control subgroup and the large sample size (≥500) subgroup, but not in the hospital-based case-control subgroup or the small sample size (\<500) subgroup. Therefore, more rigorous and uniform studies should be conducted to accurately define these associations.

Strengths and limitations {#sec18-0300060520904863}
-------------------------

This study has several advantages. First, it is a comprehensive and large meta-analysis that evaluates the association of *IL10* −1082A/G polymorphism with breast cancer risk, which makes this study more powerful than prior analyses. Second, meta-analysis results showed that the GG genotype of the *IL10* −1082A/G polymorphism was associated with an increased risk of breast cancer. Finally, subgroup stratifications were designed to exclude the influence of different factors, making the statistical outcomes more precise and reliable.

There are also several study limitations. First, the raw data from the literature were limited and some relevant studies were excluded from the final analyses because of inclusion criteria, as shown in [Figure 1](#fig1-0300060520904863){ref-type="fig"}. In three relevant articles, we could not extract the data we wanted.^[@bibr42-0300060520904863][@bibr43-0300060520904863]--[@bibr44-0300060520904863]^ Second, the sample sizes in some subgroups were small. Third, there were inconsistencies in the types of controls across studies. Control group samples included those from population-based healthy individuals and from hospitalized patients without cancer. Thus, samples from control groups may not represent the potential source population, especially in cases where the polymorphism affects the risk of other diseases. Finally, this study was based on unadjusted data. A more accurate study could be performed if data from individuals were available.

Despite the above limitations, our meta-analysis suggested that the *IL10* −1082A/G polymorphism (rs1800896) is closely associated with breast cancer risk. Future investigations to estimate the effects of gene--gene and gene--environment interactions on breast cancer are necessary for a better understanding of these interactions. Stratification by ethnicity, cancer type, study design, and sample size should be standardized in future studies on the genetics of breast cancer, which should also consider correlations between the *IL10* −1082A/G polymorphism and breast cancer risk.
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